A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALAB SEC filings page.
Astera Labs (ALAB) reported $1.6B in revenue over the twelve months to Sep 30, 2026, up 115.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Astera Labs has moved from R&D-heavy losses to profitable, cash-generating growth while keeping gross margins broadly intact.
The earnings inflection is cash-backed: FY2025 operating cash flow was$319M , or145.7% of net income, while free cash flow reached$282M after capital spending equal to11.8% of operating cash flow. That contrasts with FY2024, when free cash flow was$102M despite a net loss of$83.4M , showing that cash generation preceded reported profitability rather than merely following it.
Revenue more than doubled in FY2025 while gross margin slipped only
The balance sheet is now equity-funded: FY2025 liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Astera Labs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Astera Labs scores 26/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Astera Labs scores 99/100 on it among other operating companies.
Astera Labs carried $0.12 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Astera Labs is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 90/100 among other operating companies measured the same way.
Astera Labs held $10.24 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 10.24. Liquidity ranks operating companies on that ratio, and Astera Labs scores 98/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Astera Labs scores 88/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Astera Labs scores 26/100 on it among other operating companies.
Astera Labs scores 114.35, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $31.5B against total liabilities of $168.2M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Astera Labs passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, Astera Labs generates $1.46 in operating cash flow ($319.3M OCF vs $219.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Astera Labs generated $584.9M in revenue in Q3 2026. This represents an increase of 153.7% from the same quarter a year earlier. Against the prior quarter it is up 49.1%.
Astera Labs's EBITDA was $184.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 223.6% from the same quarter a year earlier. Against the prior quarter it is up 97.7%.
Astera Labs reported $182.9M in net income in Q3 2026. This represents an increase of 100.8% from the same quarter a year earlier. Against the prior quarter it is up 19.5%.
Astera Labs earned $0.99 per diluted share (EPS) in Q3 2026. This represents an increase of 98.0% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.
Cash & Balance Sheet
Astera Labs generated $133.9M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 103.2% from the same quarter a year earlier. Against the prior quarter it is up 99.2%.
Astera Labs held $209.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Astera Labs's gross margin was 72.3% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 4.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Astera Labs's operating margin was 30.6% in Q3 2026, reflecting core business profitability. This is up 6.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.9 percentage points.
Astera Labs's net profit margin was 31.3% in Q3 2026, showing the share of revenue converted to profit. This is down 8.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.7 percentage points.
Astera Labs's quarterly ROE was 9.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.
Capital Allocation
Astera Labs invested $171.0M in research and development in Q3 2026. This represents an increase of 116.6% from the same quarter a year earlier. Against the prior quarter it is up 25.8%.
Astera Labs invested $45.3M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 268.6% from the same quarter a year earlier. Against the prior quarter it is up 121.4%.
Not reported for Q3 2026.
ALAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $584.9M+153.7% | $392.4M+104.5% | $308.4M+93.4% | $270.6M+91.8% | $230.6M+103.9% | $191.9M+149.7% | $159.4M+144.3% | $141.1M+179.3% |
| Cost of Revenue | $162.1M+196.1% | $104.8M+126.1% | $73.2M+82.9% | $66.1M+80.4% | $54.8M+117.2% | $46.4M+172.8% | $40.0M+171.6% | $36.6M+219.0% |
| Gross Profit | $422.8M+140.5% | $287.6M+97.6% | $235.1M+96.9% | $204.5M+95.8% | $175.8M+100.1% | $145.6M+143.2% | $119.4M+136.4% | $104.4M+167.6% |
| R&D Expenses | $171.0M+116.6% | $135.9M+103.7% | $125.6M+94.6% | $93.8M+65.9% | $78.9M+55.8% | $66.7M+66.4% | $64.6M+20.5% | $56.5M+187.6% |
| SG&A Expenses | $72.7M+75.4% | $62.4M+59.8% | $47.7M+9.4% | $43.7M-8.5% | $41.5M-10.1% | $39.1M-11.4% | $43.6M-45.5% | $47.8M+361.6% |
| Operating Income | $179.1M+223.2% | $89.2M+124.4% | $61.8M+447.9% | $67.0M+46398.6% | $55.4Mn/m | $39.8Mn/m | $11.3Mn/m | $144K-98.4% |
| EBITDA | $184.2M+223.6% | $93.1M+126.2% | $65.5M+429.1% | $69.8M+6142.1% | $56.9Mn/m | $41.2Mn/m | $12.4Mn/m | $1.1M-88.3% |
| Income Tax | $9.1Mn/m | -$50.3Mn/m | -$6.9Mn/m | $33.9Mn/m | -$24.3M-352.4% | -$560Kn/m | -$10.1M-180.3% | -$14.0Mn/m |
| Net Income | $182.9M+100.8% | $153.1M+198.9% | $80.3M+152.4% | $45.0M+82.0% | $91.1Mn/m | $51.2Mn/m | $31.8Mn/m | $24.7M+72.5% |
| EPS (Basic) | $1.05+94.4% | $0.89+187.1% | $0.47+147.4% | $0.27 | $0.54n/m | $0.31n/m | $0.19 | N/A |
| EPS (Diluted) | $0.99+98.0% | $0.83+186.2% | $0.44+144.4% | $0.25 | $0.50n/m | $0.29n/m | $0.18 | N/A |
| Diluted Shares (Avg) | 184M+1.9% | 183M+2.9% | 181M+1.7% | N/A | 181M+15.2% | 178M+14.8% | 178M | N/A |
Not reported in any period shown, so not listed: Interest Expense.
ALAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3B+64.2% | $1.9B+51.9% | $1.7B+47.9% | $1.5B+45.3% | $1.4B+42.5% | $1.3B+38.9% | $1.1B+29.7% | $1.1B+437.2% |
| Current Assets | $2.0B+51.5% | $1.7B+39.9% | $1.4B+31.3% | $1.4B+34.5% | $1.3B+36.4% | $1.2B+32.5% | $1.1B+25.9% | $1.0B+445.2% |
| Cash & Equivalents | $209.4M+49.1% | $111.5M-31.3% | $148.3M+71.6% | $167.6M+110.7% | $140.4M+11.3% | $162.3M-61.4% | $86.4M-87.6% | $79.6M+76.4% |
| Short-Term Investments | $1.2B+17.6% | $1.1B+26.4% | $1.0B+23.6% | $1.0B+22.3% | $994.0M+30.7% | $902.8M+120.2% | $838.3M+696.0% | $834.8M+701.0% |
| Inventory | $200.9M+288.9% | $113.8M+94.2% | $60.2M+17.8% | $59.0M+36.5% | $51.7M+111.6% | $58.6M+105.1% | $51.1M+72.7% | $43.2M+79.4% |
| Accounts Receivable | $284.3M+562.6% | $192.5M+691.5% | $134.8M+93.2% | $83.2M+114.4% | $42.9M+69.0% | $24.3M+9.4% | $69.8M+316.4% | $38.8M+365.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $91.6M | $91.6M | $87.7M | $19.0M | N/A | N/A | N/A | N/A |
| Total Liabilities | $300.9M+132.4% | $205.8M+51.7% | $165.3M+106.2% | $168.2M+87.5% | $129.5M+38.5% | $135.7M+93.1% | $80.1M+42.8% | $89.7M-69.5% |
| Current Liabilities | $243.6M+141.3% | $164.3M+54.4% | $125.0M+61.8% | $133.0M+53.7% | $101.0M+14.7% | $106.4M+66.0% | $77.3M+69.5% | $86.5M+146.7% |
| Non-Current Liabilities | $57.3M+101.0% | $41.5M+41.6% | $40.2M+1310.3% | $35.1M+1009.8% | $28.5M+426.4% | $29.3M+373.5% | $2.9M-72.9% | $3.2M-98.8% |
| Total Equity | $2.0B+57.2% | $1.7B+51.9% | $1.5B+43.4% | $1.4B+41.3% | $1.3B+43.0% | $1.1B+34.4% | $1.0B+28.8% | $964.8Mn/m |
| Retained Earnings | $426.7Mn/m | $243.7Mn/m | $90.6Mn/m | $10.3Mn/m | -$34.6Mn/m | -$125.8Mn/m | -$177.0Mn/m | -$208.8Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
ALAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $179.2M+129.2% | $87.7M-35.2% | $74.6M+610.2% | $95.3M+139.9% | $78.2M+23.1% | $135.4M+354.1% | $10.5M+187.6% | $39.7M+175.7% |
| Depreciation & Amortization | $5.1M+240.0% | $3.9M+178.6% | $3.7M+236.4% | $2.8M+192.2% | $1.5M+87.5% | $1.4M+100.0% | $1.1M+79.2% | $974K+80.4% |
| Stock-Based Compensation | $82.6M+102.7% | $64.0M+80.4% | $48.9M+15.2% | N/A | $40.7M-10.5% | $35.5M-17.6% | $42.4M-56.6% | N/A |
| Capital Expenditures | $45.3M+268.6% | $20.5M+911.8% | $7.6M+67.1% | $18.7M+21.0% | $12.3M-26.4% | $2.0M | $4.5M+32.6% | $15.4M+1428.0% |
| Free Cash Flow | $133.9M+103.2% | $67.2M-49.6% | $67.0M+1023.4% | $76.6M+215.7% | $65.9M+40.7% | $133.3M | $6.0M+2516.2% | $24.3M+81.2% |
| Investing Cash Flow | -$81.2Mn/m | -$131.6Mn/m | -$94.0Mn/m | -$72.8Mn/m | -$101.0Mn/m | -$63.7Mn/m | -$3.9Mn/m | -$91.4Mn/m |
| Financing Cash Flow | -$34K-103.6% | $7.0M+48.8% | $82K-78.8% | $3.7M-34.0% | $952K0.0% | $4.7Mn/m | $386K-99.9% | $5.7Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ALAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3%-4.0pp | 73.3%-2.6pp | 76.3%+1.4pp | 75.6%+1.5pp | 76.3%-1.5pp | 75.8%-2.0pp | 74.9%-2.5pp | 74.0%-3.2pp |
| Operating Margin | 30.6%+6.6pp | 22.7%+2.0pp | 20.1%+13.0pp | 24.8%+24.6pp | 24.0%+31.9pp | 20.7%+52.4pp | 7.1% | 0.1%-17.8pp |
| Net Margin | 31.3%-8.2pp | 39.0%+12.3pp | 26.0%+6.1pp | 16.6%-0.9pp | 39.5%+46.2pp | 26.7%+36.5pp | 20.0% | 17.5%-10.8pp |
| Return on Equity | 9.2%+2.0pp | 8.9%+4.4pp | 5.4%+2.3pp | 3.3%+0.7pp | 7.2%+8.0pp | 4.5%+5.4pp | 3.0%+14.6pp | 2.6% |
| Return on Assets | 8.0%+1.4pp | 7.9%+3.9pp | 4.8%+2.0pp | 2.9%+0.6pp | 6.5%+7.3pp | 4.0%+4.9pp | 2.8%+13.6pp | 2.3%-5.0pp |
| Current Ratio | 8.03-4.8x | 10.05-1.0x | 11.30-2.6x | 10.24-1.5x | 12.78+2.0x | 11.10-2.8x | 13.92-4.8x | 11.71+6.4x |
| Liabilities-to-Equity | 0.150.0x | 0.120.0x | 0.110.0x | 0.120.0x | 0.100.0x | 0.120.0x | 0.080.0x | 0.09 |
| Asset Turnover | 0.25+0.1x | 0.20+0.1x | 0.190.0x | 0.180.0x | 0.160.0x | 0.15+0.1x | 0.14+0.1x | 0.13-0.1x |
| FCF Margin | 22.9%-5.7pp | 17.1%-52.3pp | 21.7%+18.0pp | 28.3%+11.1pp | 28.6%-12.8pp | 69.5% | 3.7%+3.4pp | 17.2%-9.3pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Astera Labs ALAB | FY2025 | $852.5M | $219.1M | 25.7% | $31.5B | 71/100 |
| STMicroelectronics N.V. STM | FY2025 | $11.8B | $166.0M | 1.4% | $34.9B | 57/100 |
| United Microelectronic Corp. UMC | FY2025 | $7.6B | $1.3B | 17.0% | $30.2B | 67/100 |
| Microchip Technology Inc MCHP | FY2026 | $4.7B | $230.0M | 4.9% | $30.2B | 48/100 |
| ON Semiconductor Corp ON | FY2025 | $6.0B | $121.0M | 2.0% | $23.7B | 61/100 |
| Credo Technology Group CRDO | FY2026 | $1.3B | $472.3M | 35.4% | $18.8B | 80/100 |
Where Astera Labs Ranks
Frequently Asked Questions
Astera Labs (ALAB) reported $852.5M in total revenue for fiscal year 2025. This represents a 115.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Astera Labs (ALAB) revenue grew by 115.1% year-over-year, from $396.3M to $852.5M in fiscal year 2025.
Yes, Astera Labs (ALAB) reported a net income of $461.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $219.1M, with a net profit margin of 25.7%.
Astera Labs (ALAB) had EBITDA of $180.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Astera Labs (ALAB) had a gross margin of 75.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Astera Labs (ALAB) had an operating margin of 20.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Astera Labs (ALAB) had a net profit margin of 25.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Astera Labs (ALAB) has a return on equity of 16.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Astera Labs (ALAB) generated $281.8M in free cash flow during fiscal year 2025. This represents a 175.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Astera Labs (ALAB) generated $319.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Astera Labs (ALAB) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
Astera Labs (ALAB) invested $37.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Astera Labs (ALAB) invested $304.0M in research and development during fiscal year 2025.
Astera Labs (ALAB) had a current ratio of 10.24 as of fiscal year 2025, which is generally considered healthy.
Astera Labs (ALAB) had a liabilities-to-equity ratio of 0.12 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Astera Labs (ALAB) had a return on assets of 14.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Astera Labs (ALAB) trades at 68.3x earnings, its market capitalization divided by $461.3M net income, trailing 12 months to September 30, 2026. The market capitalization is $31.5B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Astera Labs (ALAB) trades at 20.3x sales, its market capitalization divided by $1.6B revenue, trailing 12 months to September 30, 2026. The market capitalization is $31.5B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Astera Labs (ALAB) has an Altman Z-Score of 114.35, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Astera Labs (ALAB) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Astera Labs (ALAB) has an earnings quality ratio of 1.46x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Astera Labs (ALAB) scores 71 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.